Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
GLP-1 microdosing in Puerto Rico starts with the lowest effective dose of your prescribed medication and increases gradually based on your body's response. Whether you live in Adjuntas or a smaller community, the approach is the same: your physician calibrates each dose adjustment to keep side effects minimal while your body adapts naturally to the medication.
Medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved and deliver 15-22% average body weight reduction in clinical trials. With precision microdosing, Puerto Rico patients experience fewer interruptions from side effects and better long-term adherence — meaning better results over time.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 5, 2026
Puerto Rico fully supports telehealth prescribing, allowing your physician to design and adjust your microdosing protocol remotely. All PR-licensed providers in our network follow established titration guidelines and are fully compliant with state and federal telehealth regulations — making precision GLP-1 dosing accessible, legal, and safe for every Puerto Rico patient.
Select your Puerto Rico city to connect with a physician who specializes in precision GLP-1 titration plans tailored to your needs.
GLP-1 receptor agonists are among the most rigorously studied obesity treatments, with evidence from placebo-controlled trials published in the New England Journal of Medicine:
Puerto Rico authorizes board-certified licensed physicians to prescribe FDA-approved GLP-1 medications via telehealth after a valid patient-physician relationship is established through an online consultation. GLP-1 receptor agonists are not DEA-scheduled controlled substances — no in-person visit is legally required in Puerto Rico.
GLP-1 microdosing programs are available in every neighboring state and across all 50 states — the same precision titration approach wherever you are.
Licensed telehealth GLP-1 care is available statewide. Select a city to begin your clinical assessment with a state-licensed, board-certified physician.
Local weight loss and GLP-1 providers serving the Puerto Rico area, based on Google Business listings.
Bayamón, Puerto Rico
787-235-8492
4.9/5 ★ (57 reviews)
Visit website →Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
GLP-1 microdosing starts you at the lowest effective dose and gradually increases based on your tolerance and response. It is fully available in Puerto Rico through our network of PR-licensed physicians who specialize in precision titration protocols. The entire process — from health profile to your first calibrated dose — takes under 15 minutes to begin.
Standard GLP-1 protocols can escalate doses quickly, overwhelming your digestive system and causing nausea or fatigue. Microdosing gives your body time to adapt at each dose level before increasing. Puerto Rico patients on precision titration schedules report significantly fewer side effects and better medication adherence.
Your PR-licensed physician evaluates your weight, BMI, medical history, current medications, and any previous GLP-1 experience. Based on this clinical assessment, they prescribe your optimal starting microdose and create a personalized escalation timeline — adjusting only when your body is ready.
Yes. Clinical evidence shows that gradual titration achieves equivalent long-term weight loss compared to aggressive dosing schedules. Many Puerto Rico patients actually lose more weight overall because they stay on medication longer without side-effect-related interruptions. The key is consistency, not starting dose.
Puerto Rico fully supports telehealth prescribing of FDA-approved GLP-1 medications. All physicians in our network are board-certified, PR-licensed, and follow established titration guidelines. Medications ship from licensed US pharmacies. The entire process is legal, HIPAA-compliant, and clinically sound.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
